Promising Prospects for InflaRx’s Gohibic: Buy Rating Supported by Positive Phase 3 Developments and Market Potential

Analyst Edward White from H.C. Wainwright reiterated a Buy rating on InflaRx (IFRX – Research Report) and keeping the price target at $8.00.

Edward White’s rating is based on the promising developments surrounding InflaRx’s novel treatment, Gohibic, for ulcerative pyoderma gangrenosum (PG). The drug has shown potential in its Phase 3 trial, which is expected to have an interim analysis by the end of May 2025. This trial is significant as Gohibic has already received FDA Fast Track and Orphan Drug Designations, indicating its potential importance in treating a disease with no approved therapies.
Moreover, the outcomes of the interim analysis could positively impact the stock price, especially if the trial continues with its intended or expanded sample size. Previous Phase 2a studies have demonstrated that Gohibic is well-tolerated and effective in reducing C5a concentrations, a key factor in PG. With an estimated market of 50,000 PG patients across the U.S. and Europe, and a projected 2027 launch, Gohibic’s sales are forecasted to reach $32.6 million, supporting the Buy rating.

White covers the Healthcare sector, focusing on stocks such as Valneva, Chimerix, and Karyopharm Therapeutics. According to TipRanks, White has an average return of -2.2% and a 36.27% success rate on recommended stocks.